Previous Article | Next Article ![]()
Journal of Clinical Microbiology, September 2005, p. 4834-4835, Vol. 43, No. 9
0095-1137/05/$08.00+0 doi:10.1128/JCM.43.9.4834-4835.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
and
Luis Ostrosky-Zeichner1*
Laboratory of Mycology Research, University of TexasHouston Medical School, Houston, Texas,1 University of Texas M. D. Anderson Cancer Center, Houston, Texas,2 Rockeby Biomed, Ltd., Western Australia, Australia,3 School of Biomedical Sciences, Curtin University of Technology, Bentley, Western Australia, Australia4
Received 9 February 2005/ Returned for modification 6 May 2005/ Accepted 28 June 2005
Sera from 76 immunocompetent and 293 immunocompromised subjects were assayed for anti-Candida antibodies. The sensitivity, specificity, positive predictive value, and negative predictive value for invasive candidiasis were 74%, 75%, 62%, and 84% in the immunocompetent group and 15%, 60%, 1.7%, and 93% in the immunocompromised group, respectively. Syscan3 has high negative predictive value.
Present address: AstraZeneca Pharmaceuticals, Alderly Park, Macclesfield, United Kingdom.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»